Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
CLLSolid Tumor, Adult
Interventions
DRUG

Zinc-64 Aspartate

KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).

Trial Locations (1)

01135

RECRUITING

Medical Centre of Arensia Exploratory Medicine LLC, Kyiv

All Listed Sponsors
lead

Vector Vitale LLC

INDUSTRY